Aytu BioPharma (ASDAQ: AYTU) announced that it has signed an exclusive agreement with closely held Fabre-Kramer Pharmaceuticals to commercialize Exxua—extended-release antidepressant tablets—in the U.S. market for major depressive disorder (MDD).
According to Aytu, variable milestone fees will be disbursed to Fabre-Kramer throughout the duration of the partnership.
Josh Disbrow, CEO of Aytu, stated, “We believe that the licensing of EXXUA represents a transformative milestone for Aytu and a significant advancement for patients suffering from MDD.”
He added, “More importantly, given the compelling and novel product profile of EXXUA and the unmet needs of MDD patients, we believe EXXUA can become a very important treatment option for the over 21 million Americans affected by MDD. We look forward to launching EXXUA later this year and to our exciting partnership with Fabre-Kramer Pharmaceuticals.”
Stephen Kramer, co-founder and CEO of Fabre-Kramer, commented, “We believe EXXUA will be a very important addition to physicians managing the millions of patients with depression in the U.S. and worldwide.
